A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria

Lefèvre, Anna Cecilie; Deleuran, Mette; Vestergaard, Christian

doi:10.5021/ad.2013.25.2.242

Cited by 28 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total 89 of patients with CSU were enrolled in seven studies (n = 2-28) and a significant improvement in DLQI scores was obtained following omalizumab treatment (Kai, Flohr, & Grattan, 2014;Kaplan, Joseph, Maykut, Geba, & Zeldin, 2008;Lefévre, Deleuran, & Vestergaard, 2013;Marcelino et al, 2018;Savic et al, 2015;Subramaniyan & Chopra, 2016;Vestergaard & Deleuran, 2010). Accordingly with our results, the decrease in DLQI scores was most significant during the first month of treatment and then stabilized as long as the treatment is continued (Kai et al, 2014;Lefévre et al, 2013;Vestergaard & Deleuran, 2010 Consistently with our findings, two previous studies including 14 and 18 patients have reported a significant decrease in CU-Q2oL-total scores which was maintained up to 6 months (Büyüköztürk et al, 2012;Larrea-Baca & Gurpegui-Resano, 2017). Accordingly with the present study, in a recent prospective study of 117 patients, a DLQItotal score of 0/1, that indicates no effect on patients' life, has been obtained in 35.8% of the patients at third month (Ghazanfar, Holm, & Thomsen, 2018).…”

Section: Discussionmentioning

confidence: 99%

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

Salman

Demir

Bekiroğlu

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Background Omalizumab is a third‐line treatment for chronic spontaneous urticaria (CSU). However, the real‐life data on the impact of omalizumab on CSU‐related quality of life (QoL) remain scarce. Objectives To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU‐Q2oL). Results Forty‐two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment (p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0–1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU‐Q2oL scores were lower at the baseline in complete responders (p = .0001). Conclusions A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU‐Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

Salman

Demir

Bekiroğlu

2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Reported long‐term studies of omalizumab treatment of chronic urticaria are summarized in Table . Complete response or complete control of CSU symptoms were mentioned in most studies but information on other treatments during response was inexact.…”

Section: Discussionmentioning

confidence: 99%

Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients

Kulthanan

Tuchinda

Likitwattananurak

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

Omalizumab has been approved for the treatment of recalcitrant chronic spontaneous urticaria (CSU). However, it remains unanswered whether omalizumab modifies a CSU course. We aimed to study a course of CSU after omalizumab treatment in an Asian population. Medical records of recalcitrant CSU patients who attended Siriraj Hospital between 2013 and 2017 were reviewed. All patients receiving omalizumab treatment were followed after the first injection for at least 1 year. Of 15 patients receiving omalizumab treatment, 11 patients (73.3%) responded well to 150 mg while the rest required 300 mg. The median follow-up period was 18 months (range, 13.5-25.3). Three patterns of response were proposed and measured: excellent (disease remission over than 6 months) was found in 20%; good (injection interval extended longer than 6 months) was found in 27%; and modest (frequently required injections) was found in 53%. The mean duration of complete remission was 33 weeks (range, 26-38). Two-thirds of patients had disease relapse and required omalizumab injections to control symptoms. The other third did not show relapses for at least 69 weeks of the follow-up period. After 1 year of treatment, Kaplan-Meier curves estimated that a higher percentage (86.7%) of recalcitrant CSU patients receiving omalizumab treatment would be free of symptoms (weekly Urticaria Activity Score = 0) without prednisolone and/ or cyclosporin as compared with 42% of patients not receiving omalizumab treatment. In conclusion, patients seem to be easily and safely manageable with omalizumab. Prednisolone and cyclosporin could be discontinued in all patients. Further studies are needed to conclude whether omalizumab can exactly modify CSU.

show abstract

“…A typical dose of 150 mg every 2nd/4th week or 300 mg/month for 4–6 doses can have lasting efficacy of up to 15 months with significant improvement in QoL [65–67]. The significant downside is the high cost associated with the treatment (1-2 subcutaneous injections/month at US $10,000/year) and its yet unknown side effects with regard to parasitic infectious disease burden with its use in India or Asia [68–70].…”

Section: Treatment Optionsmentioning

confidence: 99%

Chronic Urticaria: Indian Context—Challenges and Treatment Options

Khan

Maitra²,

Hissaria

et al. 2013

Dermatology Research and Practice

View full text Add to dashboard Cite

Urticaria is a common condition that occurs in both children and adults. Most cases have no specific allergic trigger and the aetiology of urticaria remains idiopathic and occasionally spontaneous in nature. Inappropriate advice such as avoidance of foods (milk, egg, prawn, and brinjal) is common place in certain sections of India mostly by nonspecialists that should not be routinely recommended. It is important to look for physical urticarias such as pressure urticaria in chronic cases, which may be present either alone or in combination with other causes. Autoimmune causes for chronic urticaria have been found to play an important role in a significant proportion of patients. Long-acting nonsedating antihistamines at higher than the standard doses is safe and effective. Quality of life is affected adversely in patients with chronic symptomatic urticaria and some may require multidisciplinary management.

show abstract

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria

Cited by 28 publications

References 10 publications

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients

Chronic Urticaria: Indian Context—Challenges and Treatment Options

Contact Info

Product

Resources

About